About Ya-Chun Wang
Ya-Chun Wang is a director and the chief executive officer of TCM Life Science. He is also president of its parent, TCM Biotech International.
TCM Biotech says he has 20 years of biotechnology experience in preclinical planning, drug development, clinical trials, licensing and patent work.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Ya-Chun Wang in the role, so the role may have started earlier or lasted longer.
TCM Life Science Inc. Current
Director and Chief Executive Officer
2026 – Present · Newark, DE
TCM Life Science is developing the oral, non-antibiotic U101 candidate to prevent recurrent urinary tract infections.
TI
TCM Biotech International Current
President
Key Colleagues at Startups
The people Ya-Chun Wang works with at each company, as listed on that company's latest Form D.
TCM Life Science Inc. · Form D, Oct 26, 2026
Huan-Chin Hsu
Chairman
Ya-Chun Wang in the News
- [TCM Biotech FY2026 Q3 Earnings Call] U101 U.S. Phase III Trial Launch Imminent; Subsidiary TCM Life Science Valued at $550 Million, Raising $55 Million in Series A
- 【TCM Biotech FY2026 H1 Earnings Call】U101 Phase III Enrollment Surpasses 60%, Interim Analysis Looms in Q3; FDA Greenlights 505(b)(2) Pathway Saving Tens of Millions of Dollars; U.S. Subsidiary Established to Accelerate Global Licensing